- Home
- ACRS vs ADCT Comparison
ACRS vs ADCT Comparison
Compare ACRS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ADCT
- Stock Information
- Founded
- ACRS 2012
- ADCT 2011
- Country
- ACRS United States
- ADCT Switzerland
- Employees
- ACRS N/A
- ADCT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- ADCT Health Care
- Exchange
- ACRS Nasdaq
- ADCT Nasdaq
- Market Cap
- ACRS 127.6M
- ADCT 131.8M
- IPO Year
- ACRS 2015
- ADCT 2020
- Fundamental
- Price
- ACRS $1.14
- ADCT $1.21
- Analyst Decision
- ACRS Strong Buy
- ADCT Strong Buy
- Analyst Count
- ACRS 7
- ADCT 5
- Target Price
- ACRS $11.67
- ADCT $7.75
- AVG Volume (30 Days)
- ACRS 968.2K
- ADCT 373.9K
- Earning Date
- ACRS 05-06-2025
- ADCT 05-05-2025
- Dividend Yield
- ACRS N/A
- ADCT N/A
- EPS Growth
- ACRS N/A
- ADCT N/A
- EPS
- ACRS N/A
- ADCT N/A
- Revenue
- ACRS $18,720,000.00
- ADCT $70,837,000.00
- Revenue This Year
- ACRS N/A
- ADCT $6.82
- Revenue Next Year
- ACRS $425.96
- ADCT $18.56
- P/E Ratio
- ACRS N/A
- ADCT N/A
- Revenue Growth
- ACRS N/A
- ADCT 1.84
- 52 Week Low
- ACRS $0.95
- ADCT $1.05
- 52 Week High
- ACRS $5.17
- ADCT $5.17
- Technical
- Relative Strength Index (RSI)
- ACRS 27.21
- ADCT 39.36
- Support Level
- ACRS $1.05
- ADCT $1.13
- Resistance Level
- ACRS $1.23
- ADCT $1.25
- Average True Range (ATR)
- ACRS 0.11
- ADCT 0.11
- MACD
- ACRS -0.01
- ADCT 0.00
- Stochastic Oscillator
- ACRS 16.82
- ADCT 39.51
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.